UNSPSC 51142539: Adrogolide hydrochloride

This classification denotes a dopamine agonist with the molecular formula C22H25NO4S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69MG3OZA0H, chemically known as benzo(f)thieno(2,3-c)quinoline-9,10-diol, 4,5,5a,6,7,11b-hexahydro-2-propyl-, diacetate (ester), hydrochloride, (5ar-trans)- but more generally known as adrogolide hydrochloride, which bears US NIH Compound Identifier 166543. Most nations, for tariff and trade purposes, schedule adrogolide hydrochloride under HS 29349990 and SITC 51579.

As of Q4 2014, ADROGOLIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Adrogolide hydrochloride bears US NLM identifiers UMLS ID C2347538 and NCI Concept Code C72681. SMILES: CCCC1CC2C(S1)CN[C@H]3[C@H]2C4CC(C(CC4CC3)OC(=O)C)OC(=O)C.CL.

UNSPSC 51142539 Adrogolide hydrochloride, a Commodity code, shows a significant mismatch between its nominal scope and the work actually being solicited under it in recent state and local procurement. The code designates a specific pharmaceutical compound, yet the single recent opportunity tagged to it — Seminole County, Florida's IFB60459723LAS — solicits naloxone and drug deactivation systems for community health support, not adrogolide. The county is procuring 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors must include all shipping and delivery costs in their proposals, maintain drug-free workplace certification and E-Verify compliance, and carry workers' compensation, commercial general liability, and professional liability insurance. The contract carries a two-year initial term with a one-year renewal option and a three-month probationary period permitting termination without cause.

The code demonstrates minimal recent activity and lacks meaningful geographic or issuing-body concentration signals. Seminole County is the sole identified recent buyer. The opportunity, posted June 30, 2026, carried a response deadline of July 26, 2023, indicating a stale or backdated record. The procurement potentially draws FEMA funding, introducing federal compliance obligations including Clean Air Act and Federal Water Pollution Control Act adherence. No set-aside designations for small businesses, minority-owned enterprises, or disadvantaged vendors are specified in the opportunity. The fundamental product mismatch — the code names a single pharmaceutical active ingredient while the actual solicitation seeks naloxone and harm-reduction systems — suggests either miscoding by the issuing body or limited genuine procurement activity under the adrogolide code within state and local government.